. . . "Havelkov\u00E1, Martina" . . "Mayer, Ji\u0159\u00ED" . "R\u00E1\u010Dil, Zden\u011Bk" . "RIV/00216224:14110/14:00073663!RIV15-MSM-14110___" . "\u0160imara, Pavel" . . . . "Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry"@en . "Stejskal, Stanislav" . "P(ED1.1.00/02.0068), P(GBP206/12/G151), P(GBP302/12/G157)" . "14"^^ . . "000334070900005" . "Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry"@en . . . "Krontor\u00E1d Koutn\u00E1, Irena" . "Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry" . "14110" . . "Analytical Letters" . "11"^^ . . "[11637BC30216]" . "10.1080/00032719.2013.860538" . "Zdr\u00E1hal, Zbyn\u011Bk" . . "Determination of Imatinib in the Blood Cells of Chronic Myelogenous Leukemia Patients by Ion-Trap Mass Spectrometry" . . . . . "R\u00E1zga, Filip" . . . . "9"^^ . "Pot\u011B\u0161il, David" . "6" . "10779" . . "Borsk\u00FD, Marek" . "0003-2719" . . "RIV/00216224:14110/14:00073663" . . "Dvo\u0159\u00E1kov\u00E1, Dana" . "Imatinib mesylate is a standard first-line therapy for patients with chronic myelogenous leukemia. However, there is still a significant proportion of these patients who reflect sub-optimal responses or fail imatinib therapy. Knowledge of the distribution within the studied system (e.g., peripheral blood) may be of high importance for understanding the principles of drug action and possible patient resistance to treatment. Intracellular or more precisely cell-associated, imatinib concentrations in patients, were shown to be higher compared to those in plasma, but still only limited data related to the methodology aspects of cell-associated concentrations are available. Herein is presented an assessment of the cell-associated imatinib determination assay by mass spectrometry. Three approaches were evaluated to isolate cells from the peripheral blood of chronic myelogenous leukemia patients. Erythrocyte lysis was found to cause substantial leakage of cell-associated imatinib in the first step."@en . "47" . . "Mass spectrometry; Flow cytometry; Cell isolation technique; Chronic myelogenous leukemia; Imatinib; Peripheral blood"@en . . "US - Spojen\u00E9 st\u00E1ty americk\u00E9" . . . "Imatinib mesylate is a standard first-line therapy for patients with chronic myelogenous leukemia. However, there is still a significant proportion of these patients who reflect sub-optimal responses or fail imatinib therapy. Knowledge of the distribution within the studied system (e.g., peripheral blood) may be of high importance for understanding the principles of drug action and possible patient resistance to treatment. Intracellular or more precisely cell-associated, imatinib concentrations in patients, were shown to be higher compared to those in plasma, but still only limited data related to the methodology aspects of cell-associated concentrations are available. Herein is presented an assessment of the cell-associated imatinib determination assay by mass spectrometry. Three approaches were evaluated to isolate cells from the peripheral blood of chronic myelogenous leukemia patients. Erythrocyte lysis was found to cause substantial leakage of cell-associated imatinib in the first step." . .